Nothing makes sense.
The dosing formulation can be abused?[according to the fda reviewers who are on payroll from competitors] I do not think it should be rejected on that premise, not when comparing it to other approvals. And even at that, Mr. Market is just trying to scare you. ALKS will hit 27 by December 2013, if the eps forecasts are believable.